TTNP
(NASDAQ)
0.2482
-0.0043  (-1.74%)
Volume (24h): 4.90M Day Range: 0.2451 - 0.2644
Market Cap: 20.43M 52W Range: 0.1420 - 2.45
Jan-13-20 01:00PM Titan Pharmaceuticals Announces Addition Of Probuphine® To Federal Supply SchedulePR Newswire
Jan-07-20 02:15PM Titan Pharmaceuticals Announces Pricing of $2.2 Million Registered Direct OfferingPR Newswire
Dec-30-19 01:00PM Titan Pharmaceuticals Appoints Dr. Kate DeVarney To Its Board Of DirectorsPR Newswire
Dec-17-19 03:30PM Should You Worry About Titan Pharmaceuticals, Inc.'s (NASDAQ:TTNP) CEO Pay?Simply Wall St.
Dec-04-19 06:22PM Edited Transcript of TTNP earnings conference call or presentation 14-Nov-19 9:30pm GMTThomson Reuters StreetEvents
Dec-03-19 02:00PM Titan Pharmaceuticals To Present At The First Annual BioTuesdays Pre-JPM Virtual ConferencePR Newswire
Nov-25-19 10:15AM TTNP: Waiting for Revenue TurnZacks Small Cap Research
Nov-14-19 09:03PM Titan Pharmaceuticals Reports Third Quarter 2019 Financial ResultsPR Newswire
Nov-07-19 09:30PM Titan Pharmaceuticals To Release Third Quarter 2019 Financial Results On November 14 - Conference Call To FollowPR Newswire
Oct-22-19 12:00PM Titan Pharmaceuticals To Present Two Posters On Probuphine® At The 10th American Conference On PharmacometricsPR Newswire
Oct-18-19 02:23PM These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this yearAmerican City Business Journals
Oct-16-19 01:20PM Titan Pharmaceuticals Announces Pricing Of $9.0 Million Underwritten Public OfferingPR Newswire
Oct-01-19 12:00PM Titan Pharmaceuticals and Crossroads of Southern Nevada Announce Probuphine® Availability at Crossroads Rehabilitation FacilitiesPR Newswire
Sep-18-19 12:00PM Titan Receives Approval For Second Year Of NIDA Grant Funding For Development Of A Nalmefene ImplantPR Newswire
Aug-31-19 12:01AM Edited Transcript of TTNP earnings conference call or presentation 14-Aug-19 8:30pm GMTThomson Reuters StreetEvents
Aug-30-19 04:38AM Edited Transcript of TTNP earnings conference call or presentation 14-Aug-19 8:30pm GMTThomson Reuters StreetEvents
Aug-23-19 03:30PM TTNP: Long on Opportunity, Short on CapitalZacks Small Cap Research
Aug-17-19 01:59PM Some Titan Pharmaceuticals (NASDAQ:TTNP) Shareholders Have Copped A 99% Share Price Wipe OutSimply Wall St.
Aug-16-19 11:33AM The Daily Biotech Pulse: Roche Snags Double Nod For Personalized Cancer Drug, Bellicum Offering, Nabriva Braces For Contepo ResubmissionBenzinga
Aug-14-19 08:03PM Titan Pharmaceuticals Reports Second Quarter 2019 Financial ResultsPR Newswire
11:32AM Q2 Earnings Preview For Titan PharmaceuticalsBenzinga
Aug-09-19 09:00PM Titan Pharmaceuticals To Release Second Quarter 2019 Financial Results On August 14 - Conference Call To FollowPR Newswire
Aug-07-19 01:15PM Titan Pharmaceuticals Announces Pricing Of $2.1 Million Registered Direct OfferingPR Newswire
Jul-09-19 01:00PM Titan Pharmaceuticals Expands Patient Access To Probuphine® Via Specialty Product Distribution Agreement With CVS CaremarkPR Newswire
Jul-03-19 02:54PM What Does Titan Pharmaceuticals, Inc.'s (NASDAQ:TTNP) Balance Sheet Tell Us About It?Simply Wall St.
Jun-26-19 01:10PM Titan Pharmaceuticals And Molteni Receive European Regulatory Approval For ProbuphinePR Newswire
Jun-04-19 11:00AM Titan Pharmaceuticals Partners With Southside To Further Expand Specialty Pharmacy Network For Probuphine®PR Newswire
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)